Abstract
Aims: The present study evaluates the effect of antenatal lamotrigine exposure, on short- and long-term paediatric outcome. Methods: The study included the children of 83 epileptic women treated with lamotrigine during pregnancy, at a tertiary medical centre between 2004–2014. All newborns were monitored for vital signs, congenital malformations and Finnegan score. In addition, the parents completed a questionnaire regarding their child's development and health up to the age of 12 years. Results: No major malformations were found in the newborns. None of the newborns had significant withdrawal symptoms by Finnegan score. The children were followed-up to the age of 12 years (56.6% were 6–12 years at the time of evaluation). There were no significant findings in the incidence of neurodevelopmental disorders. Conclusions: According to our experience, lamotrigine is generally safe for pregnancy use, associated with minimal short-term complications with no long-term effects on the outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 189-194 |
| Number of pages | 6 |
| Journal | British Journal of Clinical Pharmacology |
| Volume | 84 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Jan 2018 |
| Externally published | Yes |
Keywords
- in utero
- lamotrigine
- neonatal
- neurodevelopmental
- outcome
- pregnancy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)